ZV0203

· Hangzhou Adcoris Biopharmacy Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ZV0203, covering 2025-09-30 to 2025-09-30. Get the full timeline:

Most recent: Clinical Trial Update: Study of ZV0203 in Patients With HER2-Positive Advanced Solid Tumors [Phase 1]